Last reviewed · How we verify
Counseling +CHC
Counseling +CHC is a Small molecule drug developed by Friends Research Institute, Inc.. It is currently in Phase 3 development for Substance use disorder (likely opioid or stimulant use disorder), Medication adherence support in addiction treatment. Also known as: Suboxone.
Counseling combined with contingency management (CHC) uses behavioral reinforcement and motivational interviewing to modify substance use behaviors.
Counseling combined with contingency management (CHC) uses behavioral reinforcement and motivational interviewing to modify substance use behaviors. Used for Substance use disorder (likely opioid or stimulant use disorder), Medication adherence support in addiction treatment.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Counseling +CHC |
|---|---|
| Also known as | Suboxone |
| Sponsor | Friends Research Institute, Inc. |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Substance Use Disorder |
| Phase | Phase 3 |
Mechanism of action
This is a psychosocial intervention rather than a pharmacological drug. It combines counseling—including cognitive-behavioral therapy and motivational enhancement—with contingency management (incentive-based reinforcement), where patients receive rewards for meeting treatment goals such as abstinence or medication adherence. The approach targets the behavioral and psychological drivers of substance use disorders.
Approved indications
- Substance use disorder (likely opioid or stimulant use disorder)
- Medication adherence support in addiction treatment
Common side effects
Key clinical trials
- The Effect of Chiropractic Care on Opioid Use for Chronic Spinal Pain: A Feasibility Study (NA)
- Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study (NA)
- Early Digi-physical Support During Breastfeeding Initiation (NA)
- Increasing Availability and Acceptability of Circumcision in Zambia (NA)
- Multidisciplinary Support Program in Chronic Hepatitis C
- Buprenorphine for Prisoners (PHASE3)
- mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease (NA)
- The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Counseling +CHC CI brief — competitive landscape report
- Counseling +CHC updates RSS · CI watch RSS
- Friends Research Institute, Inc. portfolio CI
Frequently asked questions about Counseling +CHC
What is Counseling +CHC?
How does Counseling +CHC work?
What is Counseling +CHC used for?
Who makes Counseling +CHC?
Is Counseling +CHC also known as anything else?
What development phase is Counseling +CHC in?
Related
- Manufacturer: Friends Research Institute, Inc. — full pipeline
- Therapeutic area: All drugs in Psychiatry / Substance Use Disorder
- Indication: Drugs for Substance use disorder (likely opioid or stimulant use disorder)
- Indication: Drugs for Medication adherence support in addiction treatment
- Also known as: Suboxone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing